Target intelligence / Profile preview

Low-affinity nerve growth factor receptor (truncated) (ΔLNGFR)

Target
ΔLNGFR
Molecular classification
Receptor, Tumor necrosis factor receptor superfamily
01

Overview

ΔLNGFR (truncated Low-Affinity Nerve Growth Factor Receptor), also known as truncated CD271 or p75NTR, is a modified version of the human nerve growth factor receptor that lacks the intracellular signaling domain [1]. It is extensively used in adoptive immunotherapy and gene therapy as a non-immunogenic surface marker to identify, enrich, and track transduced cells, such as CAR-T cells or hematopoietic stem cells [2]. Because the cytoplasmic signaling tail is removed, the molecule cannot transmit biological signals, preventing it from interfering with the host cell's function or promoting unintended cellular responses [3]. In clinical applications, ΔLNGFR allows for the high-purity selection of engineered cells using clinical-grade magnetic-activated cell sorting (MACS) [4]. Additionally, it can serve as a target for antibody-mediated depletion of engineered cells in the event of severe adverse effects, acting as a component of a safety switch system [5].

Other names
CD271p75NTRTNFRSF16dLNGFRTruncated nerve growth factor receptorp75 neurotrophin receptorTumor necrosis factor receptor superfamily member 16
02

Mechanism of action

Acts as a non-immunogenic surface marker for the enrichment, tracking, and potential depletion of genetically modified cells in adoptive cell therapy.

03

Biological functions

Cell selectionCell trackingReporter gene expressionSafety switch component
04

Disease associations

CancerGenetic disordersGraft-versus-host disease
05

Safety considerations

Potential immunogenicity of the truncated proteinEndogenous expression on mesenchymal stem cells and certain neuronal populations which may lead to off-target depletion if used as a suicide switchPotential for residual signaling if truncation is incomplete
06

Interacting drugs

Anti-CD271 monoclonal antibodies
07

Biomarkers

CD271 surface expression

Beyond the preview

Go deeper on Low-affinity nerve growth factor receptor (truncated) (ΔLNGFR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Low-affinity nerve growth factor receptor (truncated) (ΔLNGFR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call